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Abstract
Purpose The potential of desflurane to alter respiratory
mechanics in the presence of bronchial hyperresponsiveness
(BHR) is still a subject of debate. Accordingly, we evaluated
the bronchoprotective potential of desflurane compared with
sevoflurane following cholinergic lung constriction in rab-
bits with normal and hyperreactive airways.
Methods The input impedance of the respiratory system
(Zrs) was measured during midazolam-based anesthesia
before and during intravenous infusions of increasing
doses of methacholine (MCh). The rabbits in the control
group (Group C) were then randomized to receive either
sevoflurane 1 MAC followed by desflurane 1 MAC or vice
versa, whereas ovalbumin-sensitized rabbits received
sevoflurane followed by desflurane (Group S-SD) or vice
versa (Group S-DS). Baseline Zrs measurements and the
MCh provocations were repeated under the maintenance of
each volatile agent. Airway resistance (Raw), tissue
damping (G), and elastance data were obtained from Zrs
by model fitting.
Results Similar bronchoprotective effects of sevoflurane
and desflurane against MCh-induced bronchoconstriction
were observed independently of the severity of the bron-
chospasm and the presence of BHR. With sevoflurane, the
decreases in Raw ranged from 22 (8.8)% to 44 (12)%, and
with desflurane, they ranged from 22 (8.7)% to 50 (12)%.
The increases in G reflecting the enhanced ventilation
heterogeneities in the lung periphery were not affected by
the volatile agents.
Conclusions If the contractile stimulus is cholinergic in
origin, sevoflurane and desflurane exert similar broncho-
protective potentials to act against lung constriction
independent of the presence of BHR. These volatile anes-
thetics otherwise lack a potential to improve the enhanced
ventilation heterogeneities that develop particularly in the
presence of BHR.
Re´sume´
Objectif Le potentiel de desflurane a` alte´rer r la
me´canique respiratoire en pre´sence d’hyperre´activite´
bronchique (HRB) est encore sujet a` controverse. C’est
pourquoi nous avons e´value´ le potentiel de protection
bronchique du desflurane par rapport au se´voflurane a` la
suite d’une constriction pulmonaire cholinergique chez des
lapins pre´sentant des voies ae´riennes normales et
hyperre´actives.
Me´thode L’impe´dance dusyste`me respiratoire (Zrs) a e´te´
mesure´e pendant une anesthe´sie re´alise´e a` l’aide de
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midazolam avant et pendant des perfusions intraveineuses
de doses croissantes de me´thacholine (MCh). Les lapins du
groupe te´moin (groupe C) ont ensuite e´te´ randomise´s a`
recevoir soit 1 MAC de se´voflurane suivi de 1 MAC de
desflurane ou vice versa, alors que les lapins sensibilise´s a`
l’ovalbumine ont rec¸u du se´voflurane suivi de desflurane
(groupe S-SD) ou vice versa (groupe S-DS). Les mesures de
base de la Zrs et les provocations a` la MCh ont e´te´ re´pe´te´es
pendant le maintien de chaque agent volatil. Les donne´es
concernant la re´sistance des voies ae´riennes (Raw), la
composante re´sistive (G) et l’e´lastance du syste`me
respiratoire ont e´te´ obtenues de la Zrs par ajustement du
mode`le.
Re´sultats Nous avons observe´ des effets bronchoprotecteurs
semblables contre la bronchoconstriction induite par la
MCh avec le se´voflurane et le desflurane, inde´pendamment
de la gravite´ du bronchospasme et de la pre´sence d’HRB.
Avec le se´voflurane, les re´ductions de Raw se situaient entre
22 (8,8) % et 44 (12) %; avec le desflurane, elles se situaient
entre 22 (8,7) % et 50 (12) %. Les augmentations de G,
refle´tant une augmentation de l’inhomoge´ne´ite´ ventilatoire
en pe´riphe´rie des poumons, n’ont pas e´te´ affecte´es par les
agents volatils.
Conclusion Si le stimulus contractile est d’origine
cholinergique, le se´voflurane et le desflurane exercent des
potentiels de bronchoprotection semblables contre la
constriction pulmonaire, inde´pendamment de la pre´sence
d’HRB. Ne´anmoins, ces agents anesthe´siques volatils
ne posse`dent pas d’autre potentiel pour ame´liorer
l’augmentation de l’he´te´roge´ne´ite´ ventilatoire qui se
manifeste particulie`rement en pre´sence d’HRB.
Bronchospasm is one of the most challenging of the
adverse respiratory events that occur during anesthesia, and
it contributes greatly to perioperative morbidity.1 This
complication is manifested in a severe occasionally life-
threatening form, particularly in the presence of respiratory
diseases with associated bronchial hyperreactivity (BHR).
As a consequence of the increasing impact of allergens
worldwide, anesthesiologists are confronted ever more
frequently to manage patients with chronic respiratory
diseases associated with BHR.
The autonomic nervous system is of considerable
importance in the development of bronchospasm that is
associated with BHR. The parasympathetic nervous system
is primarily involved in the vagally induced lung con-
striction via stimulation of the muscarinic receptors by
acetylcholine.2 Studies performed in various animal mod-
els of chronic pulmonary diseases provide increasing
evidence that alterations in the non-adrenergic non-cho-
linergic autonomic nervous system (NANC) may also play
an important role in the development of BHR via liberation
of proinflammatory mediators that modulate airway reac-
tivity.3,4 Differences in the actions of these pathways were
highlighted by demonstrating that cholinergic stimulation
acting on the muscarinic receptors provokes primarily a
central airway constriction, while allergen challenge
induces adverse changes in the lung periphery.5
Among the anesthetic options for the management of
patients with BHR, volatile anesthetics are usually regar-
ded as first-line drugs for maintenance of anesthesia.
Extensive investigations have led to consistent conclusions
on the beneficial action of sevoflurane in the prevention
and/or treatment of bronchospasm by counteracting the
cholinergic stimulation of the airway smooth muscle.6-9
However, there have been conflicting results on the
potential of desflurane to alter the airway tone with various
previous studies demonstrating a reduction of broncho-
constriction6,10-15 or no effect on the basal16 or elevated
airway tone.8,17,18 Since most of the adverse respiratory
events are encountered in the presence of BHR, this dis-
crepancy may be attributed to the different actions of
desflurane on normal and allergically sensitized airways.
Bronchoconstriction following exposure to an allergen is
modulated primarily by an imbalance between the inhibi-
tory and excitatory NANC pathways. Since these pathways
play a major role in regulating the lung periphery via
various neuropeptides, and since desflurane has been
shown to stimulate the excitatory NANC activity,19 it is
possible that desflurane enhances the bronchoconstriction
occurring in the lung periphery.
The present study was therefore designed to test the
hypothesis that desflurane is able to prevent bronchocon-
striction similarly to sevoflurane even in allergically
sensitized airways if the triggering mechanism leading to
the bronchospasm is cholinergic in origin. The validity of
this hypothesis was evaluated by measuring the changes in
the airway and tissue mechanics separately in an estab-
lished model of BHR. The separate assessment of the
changes in the flow resistance of the airways (Raw) and the
viscoelastic properties of the respiratory tissues (G: tissue
damping; H: tissue elastance) from the low frequency input
impedance of the respiratory system (Zrs) may contribute
to characterize the potential preventive effects of these
volatile agents against an altered airway tone resulting
from distinct cholinergic stimulation.
Methods
Animals, sensitization
Following approval of the study protocol by the Ethics
Committee for Experimental Research of the University of
Geneva (registration number 08-47) and the Animal Welfare
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Committee (Office Ve´terinaire Cantonal de Gene`ve, regis-
tration number 1051/3403/1), studies were performed on
three groups of adult New Zealand white rabbits weighing 2-
2.5 kg. Group C (n = 7) comprised naı¨ve animals, while the
rabbits in Groups S-SD (n = 10) and S-DS (n = 8) under-
went active sensitization to ovalbumin (OVA). The
sensitization procedure involved intraperitoneal injections
of OVA 0.1 mg and aluminium hydroxide 10 mg on days 0
and 14. One week later, daily exposure to aerosolized OVA
10 mgmL-1 was administered for a 20-min period for five
consecutive days. Experiments were performed one day after
administration of the final OVA aerosol.
Anesthesia and animal preparations
Anesthesia was induced in all animals by the injection of
thiopental sodium 25 mgkg-1 iv (Nesdonal, Rhone-Pou-
lenc-Rohrer, Paris, France) via a 22G catheter introduced
into the ear vein, and anesthesia was maintained by an
intravenous infusion of benzodiazepine midazolam hydro-
chloride 0.2 mgmL-1 at a rate of 0.1-0.2 mgkg-1hr-1.
The rabbits were then tracheotomized, and a 3.5-mm-inter-
nal diameter polyethylene cannula was inserted into the
distal trachea. They were mechanically ventilated with room
air (Model 683, Harvard Apparatus, South Natick, MA,
USA), while a tidal volume of 7-9 mLkg-1, a frequency of
40 Hz, and a positive end-expiratory pressure of 2.5 cm H2O
were maintained. Fentanyl was infused at a rate of
2 lgkg-1hr-1 iv to ensure an adequate level of analgesia.
Muscle relaxation was achieved with atracurium besylate
2.5 mgmL-1 at a rate of 0.5-1.0 mgkg-1hr-1. Anesthetic
agents were administered by an infusion pump via the mar-
ginal ear vein. Arterial blood samples were analyzed
radiometrically (Acid-Base Laboratory model 505, Copen-
hagen, Denmark), and the parameters of mechanical
ventilation were adjusted to maintain normal gas exchange if
necessary. The concentrations of end-tidal O2 and CO2 were
monitored throughout the study (UltimaTM, Datex/Instru-
mentarium, Helsinki, Finland). Airway pressures were
measured continuously with a calibrated pressure transducer
(Validyne DP45, Northridge, CA, USA).
The carotid artery was cannulated for continuous arterial
blood pressure monitoring (Honeywell, model 156 PC
06-GW2, Zurich, Switzerland), and the jugular vein was
also cannulated for methacholine (MCh) delivery. Rectal
temperature was monitored with a temperature sensor
(Thermalert model TH-8, Physitemp, Clifton, NJ, USA)
and was maintained at 39.3 (0.5)C with a heating pad
(Miostar, Zurich, Switzerland). Airway and arterial pres-
sures, heart rate, and rectal temperature were displayed and
stored on a computer at a sampling rate of 50 Hz via an
analogue/digital interface converter (Biopac Systems, Inc.,
Santa Barbara, CA, USA).
Forced oscillatory measurements
The measurement set up used to collect input impedance
data for the total respiratory system (Zrs) was described in
detail previously.20 Briefly, the endotracheal tube was
switched to a loudspeaker-in-box system at end-expiration.
The loudspeaker generated a small-amplitude pseudoran-
dom signal containing 15 noninteger multiple components
in the frequency range 0.5-21 Hz through a 100-cm-long 5-
mm-internal diameter polyethylene wave tube. Lateral
pressures were measured at the loudspeaker (Pbox) and the
tracheal end (Ptr) of the tubing with two identical miniature
pressure transducers (ICS model 33NA002D). The Pbox
and Ptr signals were low-pass filtered and digitized by an
analogue-to-digital board of a computer at a sampling rate
of 128 Hz. The pressure-transfer functions Pbox/Ptr were
computed by fast Fourier transformation from the 8-s
recordings by using a four-second time window and 95%
overlapping. The Zrs was calculated as the load impedance
of the wave tube.20
Separation of airway and tissue mechanical properties
A well-established and verified20,21 linear model contain-
ing a frequency-independent airway resistance (Raw) and
inertance in series with the tissue damping (G) and elas-
tance (H) of a constant-phase tissue compartment22 was
fitted to the Zrs spectra by minimizing the weighted dif-
ference between the measured and the modelled impedance
data:
Zrs ¼ Raw þ jxIaw þ G  jHð Þ=xa
where j is the imaginary unit, x is the angular frequency,
and a = 2/p arctan (H/G).
Study protocol
The experimental timeline and the protocol groups are
shown in Fig. 1. When stable respiratory mechanical and
systemic hemodynamic conditions had been established,
4-6 Zrs recordings were collected in all animals to establish
the baseline. Increasing doses of MCh were then infused
through the jugular venous line at rates of 2.5, 5, and
10 lgkg-1min-1. A period of six minutes was allowed
after the onset of each MCh perfusion, and the collection of
Zrs was started at one-minute intervals thereafter until a
steady-state constriction had developed. Next, four Zrs data
epochs were collected at each infusion level under the
steady-state conditions (i.e., Raw values were within 5%)
in order to assess the lung responsiveness during intrave-
nous anesthesia. Depth of anesthesia was then altered in
accordance with the group allocation of the animals: the
rabbits in Group C were assigned randomly to receive
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either 3.7% sevoflurane (n = 3) or 8.9% desflurane
(n = 4) first (the concentration of anesthetic volatile agent
corresponding to 1 MAC)23; the animals in Group S-SD
received sevoflurane first followed by desflurane, whereas
the reverse sequence of administering the volatile agents
was used for the rabbits in Group S-DS. The random
sequencing of the volatile agents was done to minimize the
possible biasing effect of measurement times and the
interactions between them.
After establishment of a steady-state concentration of
the first volatile anesthetic agent, a five-minute period was
allowed for the agent to exert its effect and a series of Zrs
measurements was then performed. The dose-response
curve for increasing doses of intravenous MCh was next
recorded in the presence of the first volatile agent. After
completion of these recordings, the first volatile agent was
discontinued and maintenance of anesthesia was switched
to the second volatile agent. When the clearance of the first
volatile anesthetic had been attained (as confirmed by
exhaled gas analysis) and a steady-state concentration with
the second volatile anesthetic had been established
(approximately 15 min), another set of Zrs measurements,
including recordings of the baseline and during MCh
infusion, was obtained in the same manner as earlier.
After completion of the protocol during intravenous
anesthesia and with both volatile agents, the animals in the
sensitized groups (Groups S-SD and S-DS) received an
intravenous bolus of OVA 1 mg to validate the efficiency
of the allergen of sensitization.
Statistical analysis
Individual data points and group mean averages with
standard deviation values are reported.24 A logarithmic
transformation was applied to normalize the variables
before statistical testing. Three-way repeated measures of
analysis of variance (ANOVA) was used with within-sub-
ject factors of anesthetic agents (intravenous sevoflurane
and desflurane) and MCh dose, and between-subject factor
of sensitization (control vs sensitized) to establish the
effects of the volatile anesthetics and OVA-sensitization on
the lung responsiveness (Fig. 2). This statistical method
was used to test the hypotheses that 1) the presence of
volatile agents affect the respiratory mechanical parame-
ters; 2) the affinities of the two volatile agents (sevoflurane
and desflurane) are identical in protecting cholinergic-
induced bronchoconstriction; and 3) these affinities are
independent of the OVA-sensitization. Another three-way
repeated measures ANOVA was applied with the volatile
agent (sevoflurane and desflurane) and the MCh dose as
within-subject variables and the experimental group
(Group C, S-SD, and S-DS) as the between-subject variable
to test the hypothesis that the magnitude of bronchodilation
potential of the volatile agents were not affected by the
degree of the airway tone (Fig. 3). In case of significant
effects, pairwise comparisons of interest were performed
based on estimated marginal means to compare the lung
mechanical parameters under different conditions. Holm’s
step-down method was used to correct P values of pairwise
comparisons. The statistical tests were performed with a
SPSS statistical software package version 17 (IBM Cor-
poration, Somers, NY, USA). In each test, all reported P
values are two-sided.
Results
The effectiveness of the sensitization procedure was con-
firmed at the end of the experiment. The injection of the
allergen into the sensitized animals led to a heterogenous
Fig. 1 Experimental timeline and protocol groups
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bronchoconstriction (increases in Raw, 56-513%; P =
0.0001) and significant increases in G (15-202%; P =
0.005), while H remained unaffected (-26-33%; P = 0.94).
Ovalbumin induced similar lung responses in Groups S-SD
and S-DS (P = 0.14 and P = 0.66 for Raw and G,
respectively, data not shown). Complete recovery of all
mechanical parameters was observed following each
MCh challenge with no statistically significant changes
(P = 0.12, P = 0.1, and P = 0.28 for Raw, G, and H,
respectively).
Changes in the airway and tissue parameters during
anesthesia with intravenous or inhalation agents in the
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Fig. 2 Individual (small symbols) and group mean (SD) values (large
symbols) of airway resistance (Raw), tissue damping (G), and
elastance (H) under baseline conditions (BL) and during infusions of
increasing doses of methacholine (MCh) 2.5-10 lgkg-1min-1.
Closed symbols: data obtained in the naı¨ve animals (Group C); open
symbols: pooled data obtained in the ovalbumin-sensitized animals
(Groups S-SD and S-DS). Data were obtained during midazolam-
based intravenous anesthesia (circles) and during inhalation of
sevoflurane (squares) or desflurane (triangles). *Statistical signifi-
cance vs the corresponding value obtained during intravenous
anesthesia. Horizontal lines: mean values
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Fig. 3 The percentage ratio in the airway resistance (Raw), tissue
damping (G), and elastance (H) obtained during the inhalation agents
relative to those observed during the midazolam-based intravenous
anesthesia. Closed symbols: data obtained in the naı¨ve animals
(Group C); open symbols: data obtained in the ovalbumin-sensitized
animals (Groups S-SD and S-DS). Squares: data obtained during
inhalation of sevoflurane relative to intravenous anesthesia; triangles:
data obtained during inhalation of desflurane to intravenous anesthe-
sia. #Statistical significance vs the corresponding baseline; §Statistical
significance between the volatile agents within Group S-DS or Group
S-SD. Horizontal lines: mean values
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naı¨ve and OVA-sensitized animals are illustrated in Fig. 2.
The statistical analyses revealed that the MCh dose and the
mode of anesthesia management affected the Raw values
significantly (P \ 0.001). The between-subject effect was
not significant (P = 0.22, P = 0.56, and P = 0.57 for
Raw, G, and H, respectively), suggesting that sensitization
did not affect the parameter values. Under baseline con-
ditions, both inhalation anesthetics decreased the airway
tone significantly (P \ 0.001), whereas desflurane increased
the respiratory elastance (H) in both the naı¨ve (P = 0.005)
and the sensitized animals (P = 0.001). Methacholine
induced dose-dependent increases in Raw; these changes
were markedly greater in the sensitized animals, demon-
strating the presence of BHR (P = 0.001). The analysis
revealed strong interactions between the administration
of the inhalation agents and the magnitude of the
MCh-induced increases in Raw (P = 0.001), revealing that
the elevations in Raw were inhibited both by sevoflurane
and by desflurane, independently of the presence of BHR.
In contrast, the ANOVA did not show evidence of a
significant interaction between the effects of MCh on G
and the anesthesia technique (P = 0.72), indicating that
the anesthetic agents had no appreciable effects on the
MCh-induced increases in G.
The ratio of the airway and tissue mechanical parameters
obtained in response to the inhalation agents relative to those
observed during the intravenous anesthesia are shown in
Fig. 3. The Raw ratios were affected significantly by the
presence of the different volatile anesthetic agent (sevoflu-
rane or desflurane; P \ 0.001). Furthermore, significant
interaction was observed between the presence of the dif-
ferent volatile agents and the MCh (P = 0.047). Both
volatile agents exhibited fairly similar bronchodilation
potentials, independently of the level of the airway tone, i.e.,
the decreases in Raw in the presence of sevoflurane and
desflurane were around 30-40% during maintenance of a
basal airway tone (corresponding to an airway resistance of
around 15 cm H2O.s/l), and this inhibition was fairly similar
when the airway tone was markedly elevated (corresponding
to an airway resistance of about 70 cm H2O.s/l). Further-
more, the protective potential of the inhalation agents was
not influenced by the presence of BHR following allergic
sensitization (P = 0.76). Regarding the role of the sequence
of administration of the volatile anesthetics (i.e., whether
sevoflurane or desflurane was given first or second), we did
not observe any difference in the bronchoprotection poten-
tials of sevoflurane and desflurane (P = 0.8). However,
partitioning of the airway and tissue changes revealed that
the inhalation agents displayed variability in their abilities to
influence the different lung compartments, with a more
pronounced bronchoprotective effect of desflurane, whereas
sevoflurane was able to reverse the deleterious effects of
desflurane on the respiratory elastance.
Discussion
The results of the present study show that sevoflurane and
desflurane are similar in their abilities to prevent bron-
choconstriction of cholinergic origin occurring in
allergically sensitized airways. The bronchoprotective
potential of both volatile anesthetics was largely indepen-
dent of the degree of airway smooth muscle contraction but
limited in its extent. Separate assessment of the airway and
respiratory tissue mechanical changes revealed that both
inhalation agents act mainly on the central conducting
airways, whereas they exhibit only minor affinities to alter
the mechanical parameters related to the lung periphery.
To explore whether the effects of inhalation agents
depend on the presence of BHR, we adopted a well-validated
sensitization procedure with OVA to produce allergic
inflammation and subsequent BHR in rabbits.25,26 Indepen-
dently of the anesthetic management, the presence of airway
hyperresponsiveness to MCh that mimics cholinergic stimuli
was confirmed in the present study. Additionally, consistent
with previous results, all animals in the present study
exhibited a response to OVA, with marked increases in all
resistive mechanical parameters, confirming that the allergic
sensitization was the major cause of BHR.
The present study focused on one specific pathway
triggering lung constriction, as is commonly observed
during anesthesia following airway instrumentation and
endotracheal intubation. Since this adverse respiratory
event is controlled by activation of the cholinergic auton-
omous nervous system, we applied a common stimulus,
MCh, to activate the muscarinic receptors located primarily
in the central airways. The magnitude and the pattern of the
lung response to MCh were similar to those previously
measured in naı¨ve and sensitized animals with a similar
technique, with the dominance of Raw elevations associ-
ated with parallel increases in G and minor changes in
H.5,18,25,27 The increases in Raw proved to be related to the
decrease in the cross-sectional area of the central conduc-
tive airways. These changes were similarly prevented by
the administration of either of these volatile anesthetics,
demonstrating that these agents have a marked potential to
block a central airway constriction that develops following
cholinergic stimulation. Moreover, the increases in G
observed during MCh infusions with fairly constant H can
be attributed to the enhanced ventilation heterogeneities
that develop in the lung periphery, which was consistently
confirmed in previous studies by using foreign gases and
imaging techniques.5,21 In this scenario, neither of the
volatile anesthetics had a detectable effect on the elevated
G. Despite the strong bronchoprotective action of these
agents on the central airway tone, this finding suggests that
they have no affinity to prevent a heterogeneous deterio-
ration of the peripheral airway function. Since we observed
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a complete recovery in all mechanical parameters follow-
ing each MCh challenge, no residual effect of MCh may
have biased our results.
Desflurane is often recommended for the maintenance of
anesthesia because of its low blood solubility which allows
rapid recovery.28 However, despite its beneficial pharma-
codynamic profile, the interaction of desflurane with the
respiratory system is still a subject of debate. Evidence has
accumulated recently which suggests that this debate is
related to the distinct effect of desflurane on the neural
pathways regulating the airways.19,29 The bronchial smooth
muscle tone is regulated by two different neural pathways,
i.e., the cholinergic parasympathetic efferent system and
the NANC pathway activated by stimulation of the afferent
bronchopulmonary sensory C fibres.30,31 The allergic
inflammation that developed in the sensitized animals in
the present study was likely to affect both regulatory
mechanisms.31 Although the disturbance in the NANC
pathway was shown to be responsible for the deleterious
effects of desflurane by further elevating the airway
tone,19,29 our data demonstrate the beneficial properties of
this agent if the triggering mechanism leading to the
bronchospasm is cholinergic in origin. This finding may
explain the controversy in the literature related to the fact
that desflurane exhibits beneficial bronchoprotective prop-
erties when the airway constriction results from cholinergic
activation,6,10,11,15 whereas it may worsen the airway
constriction if this develops via the NANC pathway.19,29
A noteworthy aspect of our findings is the similarity in
magnitude of the bronchoprotective properties of sevoflu-
rane and desflurane independently of the level of airway
constriction and the presence or not of allergic airway
inflammation (Fig. 3, top). Consistent with previous results
obtained in isolated perfused rat lungs,15 both inhalation
agents inhibited basal bronchial tone by around 30-40%.
This clinically relevant magnitude of inhibition persisted if
the Raw was further increased by more than threefold
following infusion of the highest dose of MCh. This sug-
gests the presence of a threshold in the degree of
bronchoprotection by the volatile anesthetics against the
central airway constriction induced via cholinergic acti-
vation. These properties of sevoflurane and desflurane are
manifested in similar proportional decreases in Raw in
animals with normal and sensitized airways. While the
airway tone enhancement following cholinergic stimula-
tion can be prevented effectively, even in the presence of
BHR, the existence of this phenomenon suggests that
administration of the volatile agents would have the
potential to restore airway tone to a certain extent.
Whereas sevoflurane is indicated for both induction
and maintenance of general anesthesia, we recognize that,
due to moderate pungency, desflurane is indicated for
maintenance of anesthesia only. Some clinicians use
sevoflurane for the induction period then switch to des-
flurane for maintenance of anesthesia. The present study
demonstrates that the sequence of administration of these
volatile agents is immaterial as regards the airway tone
and that the extent of bronchoprotection is determined
primarily by the presence of a volatile agent rather than
the specific agent applied, no matter what the sequence of
administration.
The apparent controversy between the present findings
with desflurane and those where airway irritation was
reported previously in the presence of enhanced airway
tone8,32 ensues primarily from the differences in the initial
conditions before administering this volatile agent. Airway
constriction was present prior to desflurane inhalation both
in children with susceptible airways8 and in OVA-sensi-
tized guinea pigs,18 indicating that desflurane may exert its
deleterious effects on the airway tone only if it was already
compromised before the onset of the volatile agent. In
addition, initially impaired airway and respiratory tissue
mechanics were a consequence of a complex mechanism
involving both the cholinergic and NANC pathways in
children with susceptible airways.8 The deleterious effect
of desflurane under this scenario further confirms that this
volatile agent exerts its irritation potential via stimulation
of the NANC pathway.
In summary, the present study has demonstrated the
similar bronchoprotective potentials of sevoflurane and
desflurane against lung constriction induced by activation
of the cholinergic pathway. This ability was independent
of the presence or not of allergic inflammation in the
airways and the subsequent development of BHR. The
severity of the lung constriction induced by different
levels of MCh provocation did not influence the degree of
bronchoprotection exerted by the volatile agents studied.
When using these agents in clinical practice, our findings
suggest that clinicians should be aware that these agents
are unable to counteract an enhanced airway tone com-
pletely, and they have no beneficial profile against the
resulting ventilation inhomogeneities in the lung periph-
ery that develop, particularly in the presence of airway
hyperresponsiveness.
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